Citizens reiterates Market Outperform on Taysha Gene Therapies
Citizens analyst Silvan Turkcan has reiterated a Market Outperform rating on Taysha Gene Therapies. The firm maintains a price target of $11.

*this image is generated using AI for illustrative purposes only.
Citizens analyst Silvan Turkcan has reaffirmed a Market Outperform rating on Taysha Gene Therapies. The firm maintains a price target of $11 for the stock.
The rating reiteration underscores the analyst's continued confidence in the company's performance prospects.
What upcoming clinical milestones could drive Taysha Gene Therapies' stock toward the $11 price target?
How might recent advancements in gene therapy impact Taysha's competitive positioning?
What are the potential regulatory hurdles that could affect Taysha's growth trajectory?





























